Jamalidoust Marzieh, Namayandeh Mandana, Moghadami Mohsen, Ziyaeyan Mazyar
Department of Virology, Professor Alborzi Clinical Microbiology Research Center, Nemazi Hospital, Shiraz University of Medical Sciences, P. O. Box: 31, Shiraz, 71937-11351, Iran.
Department of Virology, Professor Alborzi Clinical Microbiology Research Center, Nemazi hospital, Shiraz University of Medical Sciences, Shiraz, 71937-11351, Iran.
Virol J. 2017 Jul 11;14(1):127. doi: 10.1186/s12985-017-0797-2.
Because of shared modes of transmission, patients with hepatitis C virus (HCV) infection are often co-infected with other types of hepatitis viruses and/or HIV. We studied HCV viral load and its genotype patterns among HCV mono- and HCV/HIV co-infected Illicit Drug Users in Fars province-Iran.
Totally, 580 HCV seropositive IDUs referred to Prof. Alborzi Clinical Microbiology Research Center, Shiraz, Iran, without receiving any anti-HCV treatment, were enrolled. After their HCV infections were reconfirmed by one step rapid diagnostic test, HCV RNA level and HCV genotypes were determined by Taq-man real-time PCR assays. Their HIV serostatus was determined and seropositive patients were excluded from the group. In addition, 104 HIV/HCV co-infected IDUs referred from Shiraz Behavioral Diseases Consultation Center (SBDC) were assessed for HCV RNA level and HCV genotype patterns, as well.
The overall estimated HIV prevalence was 6.7% (39/580) among HCV seropositive IDUs. Genotype 1, the most prevalent genotype in both groups, was detected in 69% and 49% of co- and mono-infected IDUs, respectively. Median HCV viral load was significantly higher in HIV/HCV co-infected patients, compared with that among HCV mono-infected counterparts.
Given the higher baseline HCV viral load and GT1 attributed to poorer treatments response, HCV treatment must be more considered among HCV/HIV co-infected IDUs, compared to those mono-infected with HCV.
由于传播方式相同,丙型肝炎病毒(HCV)感染患者常合并感染其他类型的肝炎病毒和/或HIV。我们研究了伊朗法尔斯省非法药物使用者中HCV单一感染和HCV/HIV合并感染患者的HCV病毒载量及其基因型模式。
共有580例未接受任何抗HCV治疗的HCV血清学阳性非法药物使用者被纳入研究,他们被转诊至伊朗设拉子的阿尔博齐教授临床微生物学研究中心。通过一步快速诊断试验再次确认其HCV感染后,采用Taq - man实时PCR测定法确定HCV RNA水平和HCV基因型。确定他们的HIV血清学状态,血清学阳性患者被排除在该组之外。此外,还对从设拉子行为疾病咨询中心(SBDC)转诊的104例HIV/HCV合并感染的非法药物使用者的HCV RNA水平和HCV基因型模式进行了评估。
在HCV血清学阳性的非法药物使用者中,总体估计的HIV患病率为6.7%(39/580)。基因型1是两组中最常见的基因型,分别在69%的合并感染和49%的单一感染非法药物使用者中检测到。与HCV单一感染的患者相比,HIV/HCV合并感染患者的HCV病毒载量中位数显著更高。
鉴于基线HCV病毒载量较高以及基因型1与较差的治疗反应相关,与HCV单一感染的患者相比,HCV/HIV合并感染的非法药物使用者必须更考虑进行HCV治疗。